Type I Diabetes Patents (Class 514/7.3)
  • Patent number: 10435428
    Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: October 8, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Ryan Hudson, Daniel D. Long, Donna A. A. Wilton, Mandy Loo, Patrick J. Brassil
  • Patent number: 9855294
    Abstract: The present invention relates to methods of managing weight, and treating overweight or obesity and treating or preventing diabetes in a subject in need thereof. In one embodiment, the method comprises the steps of (a) orally administering to the subject from about 0.7 g to about 4 g of crosslinked carboxymethylcellulose; and (b) orally administering to the subject at least about 100 mL of water per gram of crosslinked carboxymethylcellulose. Steps (a) and (b) are conducted prior to or with at least one meal per day.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: January 2, 2018
    Assignee: Gelesis, LLC
    Inventors: Hassan Heshmati, Eyal S. Ron, Alessandro Sannino, Yishai Zohar
  • Patent number: 9486414
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: November 8, 2016
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Patent number: 9457065
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: October 4, 2016
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Patent number: 9403826
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing inflammatory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of intermittent claudication resulting from obstructed arteries in the limbs, and vascular dementia, improves blood flow through peripheral blood vessels and therefore helps with blood circulation in the arms and legs (e.g.
    Type: Grant
    Filed: February 2, 2013
    Date of Patent: August 2, 2016
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Patent number: 9226914
    Abstract: Disclosed are methods for promoting neuronal health and/or development in a subject by providing nutritional compositions comprising docosahexaenoic acid and alpha-lipoic acid. The nutritional composition may further include lactoferrin, a prebiotic, a probiotic, and mixtures thereof. Additionally disclosed are methods for accelerating the development of neuronal activity and/or strengthening electrochemical synapse signaling by providing the nutritional composition(s) disclosed herein to a target subject.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: January 5, 2016
    Assignee: Mead Johnson Nutrition Company
    Inventors: Chenzhong Kuang, Yan Xiao, Eduard Poels, Zeina Jouni, Dirk Hondmann
  • Publication number: 20150147325
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
    Type: Application
    Filed: February 6, 2015
    Publication date: May 28, 2015
    Inventors: Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
  • Publication number: 20150133375
    Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 14, 2015
    Inventors: Soren Mogelsvang, Cohava Gelber
  • Patent number: 9029325
    Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: May 12, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Lauge Schaeffer, Thomas Kruse, Henning Thoegersen
  • Patent number: 9023789
    Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analog of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: May 5, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Kirsten Dahl, Lauge Schaeffer, Thomas Kruse
  • Publication number: 20150111821
    Abstract: The present disclosure provides FGF1 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such mutant FGF1 proteins can be part of a chimeric protein that includes a ?-Klotho-binding protein, an FGFR1c-binding protein, a ?-Klotho-binding protein and a FGFR1c-binding protein, a C-terminal region from FGF19 or FGF21. In some examples, mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 23, 2015
    Inventors: Jae Myoung Suh, Michael Downes, Ronald M. Evans, Annette Atkins, Ruth T. Yu
  • Publication number: 20150104388
    Abstract: This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 16, 2015
    Inventors: David H. COY, Jerome L. MADERDRUT, Min LI
  • Publication number: 20150099697
    Abstract: Described herein is a treatment comprising the following step: (a) injecting a therapeutically effective amount of a pharmaceutical composition into the celiac artery of an individual, wherein the pharmaceutical composition reverses recent onset Type 1 Diabetes (T1D). Also described is a method for identifying an individual who will be responsive to this treatment. In addition there is described a device containing the pharmaceutical composition for injecting the pharmaceutical composition into the celiac artery.
    Type: Application
    Filed: April 4, 2014
    Publication date: April 9, 2015
    Inventor: Hans-Michael DOSCH
  • Patent number: 8980244
    Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: March 17, 2015
    Assignees: Ben-Gurion University of the Negev Research and Development Authority, Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.
    Inventors: Ofer Mandelboim, Angel Porgador, Yaakov Naparstek, Chamutal Gur
  • Patent number: 8975223
    Abstract: Methods are provided for administering an extended half-life GLP-1/GIP coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: March 10, 2015
    Assignee: Marcadia Biotech, Inc.
    Inventors: Louis Vignati, Richard D. DiMarchi
  • Patent number: 8975224
    Abstract: We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: March 10, 2015
    Assignee: Serpin Pharma, LLC
    Inventors: Soren Mogelsvang, Cohava Gelber
  • Publication number: 20150051137
    Abstract: Provided is a method for treatment and/or prophylaxis of a condition associated with T cell mediated chronic inflammatory disease by administration, to a patient, of a peptide comprising N?-SVTEQGAELSNEER-C? {SEQ ID NO: 1) or an analogue thereof that inhibits T cell migration. Also provided is the peptide or its analogue for use in the methods of treatment: and/or prophylaxis of said condition.
    Type: Application
    Filed: January 14, 2013
    Publication date: February 19, 2015
    Applicant: The University of Birmingham
    Inventors: George Edward Rainger, Parth Narendran, Helen McGettrick, Myriam Chimen
  • Patent number: 8957021
    Abstract: The present invention relates to compositions comprising glucose regulating peptides linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of glucose regulating peptide-related diseases, disorders, and conditions.
    Type: Grant
    Filed: June 8, 2010
    Date of Patent: February 17, 2015
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Willem P. Stemmer, Chia-wei Wang, Nathan Geething, Jeffrey L. Cleland
  • Publication number: 20150030595
    Abstract: The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.
    Type: Application
    Filed: January 3, 2013
    Publication date: January 29, 2015
    Inventors: Dong Hee Lee, Bum Chan Park, Jae Eun Park, Myeong Hee Jang, Seok Ho Yoo, Hye Nan Kim
  • Publication number: 20150023984
    Abstract: Compositions and methods for the detection and treatment of T1D are provided.
    Type: Application
    Filed: April 14, 2014
    Publication date: January 22, 2015
    Applicant: The Children's Hospital of Philadelphia
    Inventors: Hakon Hakonarson, Jonathan Bradfield, Struan Grant, Constantin Polychronakos
  • Patent number: 8932559
    Abstract: Nuclear Transport Modifiers such as cSN50 and cSN50.1, afford in vivo islet protection following a 2-day course of intense treatment in autoimmune diabetes-prone, non-obese diabetic (NOD) mice, a widely used model of Type 1 diabetes (T1D), which resulted in a diabetes-free state for one year without apparent toxicity and the need to use insulin. cSN50 precipitously reduces the accumulation of islet-destructive autoreactive lymphocytes while enhancing activation-induced cell death of T and B lymphocytes derived from NOD mice. cSN50 attenuated pro-inflammatory cytokine and chemokine production in immune cells in this model of human T1D. cSN50 also provides cytoprotection of beta cells, therefore preserving residual insulin-producing capacity. Because intracellular delivery of a Nuclear Transport Modifier peptide such as cSN50 and cSN50.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: January 13, 2015
    Assignee: Vanderbilt University
    Inventors: Jack J. Hawiger, Robert D. Collins, Daniel J. Moore, Jozef Zienkiewicz, Ruth Ann Veach
  • Publication number: 20150010508
    Abstract: The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating islet cell neogenesis and stimulating islet cell differentiation from progenitor cells.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 8, 2015
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • Publication number: 20150011471
    Abstract: The present invention provides compositions for use in the treatment of long-established type 1 diabetes (T1D) using peptides and analogs of heat shock protein 60 (Hsp60). The invention is exemplified using DiaPep277, a peptide analog of human Hsp60, which is shown to induce increase in plasma C-peptide and regeneration of islet beta cells. The invention further relates to regimens useful for treatment of long established T1D in patients having no demonstrable islet beta cell-function.
    Type: Application
    Filed: February 28, 2013
    Publication date: January 8, 2015
    Inventors: Irun R. Cohen, Raanan Margalit
  • Patent number: 8927489
    Abstract: The present invention provides a pharmaceutical composition for the sustained release of C-peptide. The composition is in the form of a gel containing C-peptide. The gel formation is achieved by the adjustment of pH of the composition and/or by addition of divalent metal ions. The composition does not include any other gel-forming agents. Methods for producing the composition, medical uses of the composition and products containing two or more gel compositions as a combined preparation are also encompassed.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: January 6, 2015
    Assignee: Cebix Incorporated
    Inventors: John Wahren, Anders Carlsson
  • Patent number: 8916525
    Abstract: The present invention relates to TNFR2-TWEAKR fusion protein, more precisely to TNFR2-TWEAKR fusion protein acting as a double-antagonist to TNF-? and TWEAK, known as major causes of autoimmune arthritis which is one of autoimmune diseases. When the composition comprising TNFR2-TWEAKR fusion protein was treated to Th17 cells, the secretion of the inflammatory cytokine IL-17 was reduced but the secretion of the anti-inflammatory cytokine IL-10 generated in Treg cells was increased. Such effect of TNFR2-TWEAKR fusion protein was far greater than that of a single protein such as TNFR2-Fc or TWEAK-Fc. The TNFR2-TWEAKR fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: December 23, 2014
    Assignees: Korea Research Institute of Bioscience and Biotechnology, Industry-Academic Cooperation Foundation, The Catholic University of Korea
    Inventors: Young Woo Park, Ki Won Jo, Srok Ho Yoo, Jung Yu, Dong Jin Kim, Sun-Ha Yoon, Eun Jung Song, Eun Kyung Lee, Jin Mi Oh, Kyu Won Cho, Mi La Cho, Ho Youn Kim, Mi Kyung Park, Hye Jwa Oh, Jin Sil Park, Yun Ju Woo, Jae Kyeong Byun, Jun Geol Ryu
  • Patent number: 8916517
    Abstract: This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: December 23, 2014
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: David H. Coy, Jerome L. Maderdrut, Min Li
  • Publication number: 20140357557
    Abstract: Methods and compositions relating to CDP-JAK inhibitor conjugates are described herein.
    Type: Application
    Filed: May 30, 2014
    Publication date: December 4, 2014
    Applicant: CERULEAN PHARMA INC.
    Inventors: Roderic O. Cole, Derek Gregory van der Poll
  • Publication number: 20140348832
    Abstract: The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.
    Type: Application
    Filed: June 29, 2012
    Publication date: November 27, 2014
    Applicant: GENZYME CORPORATION
    Inventors: Yunxiang Zhu, Jozsef Karman, Ronnie Wei, Canwen Jiang, Seng Cheng
  • Publication number: 20140349920
    Abstract: N-acylpeptide derivatives are described. Compositions comprising N-acylpeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with tumors or cancers, immune, nervous, vascular, musculoskeletal, cutaneous system, or other tissues or systems in a subject.
    Type: Application
    Filed: January 3, 2013
    Publication date: November 27, 2014
    Inventors: Ruey J. Yu, Eugene J. Van Scott
  • Publication number: 20140349924
    Abstract: The present invention relates to shelf stable non-aqueous pharmaceutical compositions, and to the use thereof in methods of treating diabetes and hyperglycaemia.
    Type: Application
    Filed: July 21, 2014
    Publication date: November 27, 2014
    Inventors: Simon Bjerregaard Jensen, Svend Havelund, Florian A. Foeger
  • Patent number: 8895694
    Abstract: The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: November 25, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Jane Spetzler, Lauge Schäffer, Jesper Lau, Thomas Kruse, Patrick William Garibay, Steffen Reedtz-Runge, Henning Thøgersen, Ingrid Pettersson
  • Patent number: 8889133
    Abstract: The present invention provides methods of preventing, treating or ameliorating diabetes by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists that block Dll4-Notch signal pathways. As observed in a mouse model of diabetes, Dll4 antagonists exhibit protective effects on pancreatic islets, lower blood glucose levels, and block the production of auto-antibodies, including those against insulin and glutamic acid decarboxylase 65 (GAD65), via the expansion of regulatory T cells (Tregs). Thus, the present invention further provides methods of lowering the levels of blood glucose, and/or reducing or blocking the production of auto-antibodies, by administering to a subject in need thereof a therapeutically effective amount of Dll4 antagonists. Suitable Dll4 antagonists for the invention include antibodies or antibody fragments that specifically bind Dll4 and block Dll4-Notch interactions, the extracellular domain of Dll4, and the like.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: November 18, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Dimitris Skokos
  • Patent number: 8889618
    Abstract: C-Terminal Fragments of Glucagon-Like Peptide-1 (GLP 1), and methods of use thereof, e.g., for the treatment of obesity and obesity-related disorders, e.g., diabetes and the metabolic syndrome.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: November 18, 2014
    Assignee: The General Hospital Corporation
    Inventors: Joel F. Habener, Tatsuya Yano, Eva Tomas Falco
  • Publication number: 20140335108
    Abstract: The present invention is directed to compositions and methods to treat an autoimmune disease in a subject, comprising an insulin-like 6 (Insl6) agent, such as an Insl6 polypeptide or variant or fragment thereof, or a nucleic acid encoding Insl6 poly peptide or variant or fragment thereof. Aspects of the present invention relate to use of Insl6 agents to reduce T-regulatory (Treg) cells in the subject and to reduce pro-inflammatory cytokines in a subject with an autoimmune disease such as a muscle autoimmune disease. The present invention also relates to methods and kits for the treatment of autoimmune diseases in a subject, and methods to diagnose a subject with an autoimmune disease such as myositis.
    Type: Application
    Filed: December 12, 2012
    Publication date: November 13, 2014
    Inventors: Kenneth Walsh, Ling Zeng
  • Patent number: 8883721
    Abstract: The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18 (SEQ ID NO: 93), wherein each of A11, A12, and A13 is independently absent, an amino acid, or an amino protecting group; each of A15, A16, A17, and A18 is independently absent or an amino acid; and A14 is a serine conjugated with a —(O)C1-C20alky or a diaminopropionic acid conjugated with a —C(O)C1-C20alkyl group, provided that at least one of A11, A12, or A13 is present.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: November 11, 2014
    Assignees: McGill University, The Administrators of the Tulane Educational Fund
    Inventors: Cyril Y. Bowers, David H. Coy, Simon J. Hocart, Gloria S. Tannenbaum
  • Publication number: 20140328794
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.
    Type: Application
    Filed: July 18, 2013
    Publication date: November 6, 2014
    Applicant: Human Genome Sciences, Inc.
    Inventors: Craig A. Rosen, William A. Haseltine, Steven M. Ruben
  • Publication number: 20140329749
    Abstract: The present invention relates to compositions forming a low viscosity mixture of: a. 25-55 wt. % of at least one diacyl glycerol and/or at least one tocopherol; b. 25-55 wt. % of at least one phospholipid component comprising phospholipids having i. polar head groups comprising more than 50% phosphatidyl ethanolamine, and ii. two acyl chains each independently having 16 to 20 carbons wherein at least one acyl chain has at least one unsaturation in the carbon chain, and there are no more than four unsaturations over two carbon chains; c. 5-25 wt. % of at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein 0.1-10 wt. % of at least one peptide active agent comprising at least one somatostatin receptor agonist is dissolved or dispersed in the low viscosity mixture; and wherein the pre-formulation forms, or is capable of forming, at least one non-lamellar liquid crystalline phase structure upon contact with an aqueous fluid.
    Type: Application
    Filed: November 28, 2012
    Publication date: November 6, 2014
    Inventors: Fredrik Tiberg, Markus Johnsson
  • Publication number: 20140322213
    Abstract: A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a GABAergic and incretin exemplified by GABA and GLP-1/Ex4. These are optionally provided together in a single composition to promote beta-cell regeneration prevent beta-cell apoptosis and control autoimmunity for the prevention and treatment of T1D in mammals.
    Type: Application
    Filed: March 24, 2014
    Publication date: October 30, 2014
    Inventor: Qinghua Wang
  • Patent number: 8865649
    Abstract: It has been found that high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, especially in relative absence of glutamate equivalents, improve the metabolism of ketobodies and/or lactate in a mammal's body, especially in diseased or traumatic conditions. As a result, levels of ketobodies and lactate can be decreased and unphysicologically high acidity normalised. Thus, it is an object of the invention to provide an enteral nutritional or a pharmaceutical composition for the treatment and/or prevention of disturbed ketone and lactate metabolism, i.e. elevated concentrations of ketone bodies, lactate and/or other organic acids and/or insufficient pH homeostasis, especially elevated concentrations of ketone bodies and/or lactate, in a mammal's blood, wherein the composition comprises high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, preferably in relative absence of glutamate equivalents.
    Type: Grant
    Filed: August 1, 2011
    Date of Patent: October 21, 2014
    Assignee: N. V. Nutricia
    Inventor: Robert Johan Joseph Hageman
  • Publication number: 20140303080
    Abstract: N-acyldipeptide derivatives are described. Compositions comprising the N-acyldipeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with a tumor, cancer, immune, nervous, vascular, musculoskeletal or cutaneous system, or other tissue or system in a subject.
    Type: Application
    Filed: October 31, 2012
    Publication date: October 9, 2014
    Inventors: Ruey J. Yu, Eugene J. Van Scott
  • Publication number: 20140301974
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Application
    Filed: January 30, 2014
    Publication date: October 9, 2014
    Applicant: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-Wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • Publication number: 20140294851
    Abstract: Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.
    Type: Application
    Filed: April 1, 2013
    Publication date: October 2, 2014
    Inventor: MARK QUANG NGUYEN
  • Publication number: 20140294901
    Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Application
    Filed: March 28, 2014
    Publication date: October 2, 2014
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
  • Publication number: 20140296130
    Abstract: The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. peptide tight junction antagonists. The present invention also provides methods for the treatment of excessive or undesirable permeability of a tissue by administering to a subject suffering from such a condition a composition comprising a peptide tight junction antagonist of the invention.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Inventor: Amir Tamiz
  • Publication number: 20140296139
    Abstract: MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 2, 2014
    Inventors: Pinchas COHEN, Changhan LEE, Laura J. COBB
  • Publication number: 20140286906
    Abstract: The present invention relates to the use of the Insulin-like growth factor-I (IGF-1) in immune modulation and/or in the treatment or prevention of pathogenic or aberrant immune responses or disorders and/or for use in the treatment or prevention of T-cell mediated disorders or diseases and/or for use in the treatment or prevention of diseases where the immune system contributes to the disease state.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 25, 2014
    Inventors: Daniel Bilbao Cortes, Nadia Rosenthal, Luisa Luciani
  • Publication number: 20140274892
    Abstract: The present disclosure provides a method for reducing the risk of autoimmune disease by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition, may reduce the symptoms of autoimmune disease and may be a treatment for autoimmune disease, especially type 1 diabetes. Preferably, the hydrolysate consists of peptides with a molecular weight of more than 500 Da.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: MEAD JOHNSON NUTRITION (ASIA PACIFIC) PTE. LTD.
    Inventors: Dirk Hondmann, Eric A.F. van Tol, Gabriele Gross, Marieke H. Schoemaker, Teartse Tim Lambers
  • Publication number: 20140249077
    Abstract: The present invention is directed to compositions and methods of preparation of phospholipid gels.
    Type: Application
    Filed: June 8, 2012
    Publication date: September 4, 2014
    Applicants: ASTRAZENECA PHARMACEUTICALS LP, AMYLIN PHARMACEUTICALS, LLC
    Inventors: Andrew Xian Chen, Hailiang Chen
  • Publication number: 20140249072
    Abstract: The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway.
    Type: Application
    Filed: May 4, 2012
    Publication date: September 4, 2014
    Applicant: WELLSTAT IMMUNO THERAPEUTICS, LLC
    Inventors: ChangHung Chen, Michael Kaleko, Beibei Li, Tianci Luo, Jeffrey Allan Miller, Ruigong Wang
  • Publication number: 20140249081
    Abstract: The present invention relates to amylin peptide-carrying nanoparticles, particularly for use in medicine, and includes methods for treatment of disorders, e.g., of blood glucose regulation. Nanoparticle composition comprise a nanoparticle comprising a core comprising a metal and/or a semiconductor; and a corona comprising a plurality of ligands covalently linked to the core, wherein said ligands comprise glutathione; and at least one amylin peptide that is non-covalently bound to the corona.
    Type: Application
    Filed: February 6, 2014
    Publication date: September 4, 2014
    Inventors: Thomas Rademacher, Phillip Williams